Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial

Metastatic Pancreatic Adenocarcinoma

Phase 2 ◽

First Line ◽

Open Label ◽

First Line Therapy ◽

Phase 2 Trial ◽

Line Therapy ◽

P-287 Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): a randomized, open-label phase 2 study

Annals of Oncology ◽

10.1093/annonc/mdw199.277 ◽

2016 ◽

Vol 27 ◽

pp. ii84

Author(s):

Dean Andrew ◽

Ramanathan Ramesh ◽

Belota Brooke ◽

Belanger Bruce ◽

Adib Deyaa ◽

...

Keyword(s):

Phase 2 ◽

First Line ◽

Open Label ◽

First Line Therapy ◽

Line Therapy ◽

Metastatic Pancreatic Adenocarcinoma ◽

Phase 2 Study ◽

Open Label Phase ◽

Nanoliposomal Irinotecan

Eltrombopag and Cyclosporine as First-Line Therapy in Patients with Severe Acquired Aplastic Anemia: A Two-part, 5-year, Single-Arm, Multicenter, Open-label, Phase 2 Trial (SOAR)

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2017.07.242 ◽

2017 ◽

Vol 17 ◽

pp. S389-S390

Author(s):

Phillip Scheinberg ◽

Joan Maier ◽

Ozlem Ocak Arikan ◽

Carlo Finelli ◽

Junho Jang

Keyword(s):

Aplastic Anemia ◽

Phase 2 ◽

First Line ◽

Open Label ◽

First Line Therapy ◽

Phase 2 Trial ◽

Line Therapy ◽

Open Label Phase

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(14)70381-x ◽

2014 ◽

Vol 15 (11) ◽

pp. 1236-1244 ◽

Cited By ~ 383

Author(s):

Takashi Seto ◽

Terufumi Kato ◽

Makoto Nishio ◽

Koichi Goto ◽

Shinji Atagi ◽

...

Keyword(s):

Small Cell ◽

Egfr Mutations ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Multicentre Phase ◽

First Line Therapy ◽

Line Therapy ◽

Phase 2 Study

North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma

Cancer ◽

10.1002/cncr.30766 ◽

2017 ◽

Vol 123 (18) ◽

pp. 3494-3501 ◽

Cited By ~ 13

Author(s):

Robert R. McWilliams ◽

Nathan R. Foster ◽

Michelle R. Mahoney ◽

Thomas C. Smyrk ◽

Joseph A. Murray ◽

...

Keyword(s):

Treatment Group ◽

Small Bowel ◽

Cancer Treatment ◽

Small Bowel Adenocarcinoma ◽

Phase 2 ◽

First Line ◽

North Central ◽

First Line Therapy ◽

Phase 2 Trial ◽

Abstract B14: CA 19-9 levels in patients with metastatic pancreatic adenocarcinoma receiving first-line therapy with liposomal irinotecan plus 5-fluorouracil/leucovorin and oxaliplatin (NAPOX)

10.1158/1538-7445.panca19-b14 ◽

2019 ◽

Author(s):

Farshid Dayyani ◽

Patrick M. Boland ◽

Andrew Dean ◽

Christopher H. Lieu ◽

Teresa Macarulla ◽

...

Keyword(s):

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Metastatic Pancreatic Adenocarcinoma ◽

Liposomal Irinotecan

DISRUPT: A randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane–platinum regimen as first-line therapy for metastatic non-small cell lung cancer

Lung Cancer ◽

10.1016/j.lungcan.2014.05.013 ◽

2014 ◽

Vol 85 (2) ◽

pp. 224-229 ◽

Cited By ~ 15

Author(s):

Joachim von Pawel ◽

Vera Gorbounova ◽

Martin Reck ◽

Dariusz M. Kowalski ◽

Aurore Allard ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Phase 2 Trial ◽

Abstract CT139: First-line therapy with dacomitinib, an orally available pan-her tyrosine kinase inhibitor, for locally-advanced or metastatic penile squamous cell carcinoma: Results of an open label, single-arm, single-center, phase 2 study

10.1158/1538-7445.am2017-ct139 ◽

2017 ◽

Author(s):

Andrea Necchi ◽

Salvatore Lo Vullo ◽

Daniele Raggi ◽

Patrizia Giannatempo ◽

Nicola Nicolai ◽

...

Keyword(s):

Kinase Inhibitor ◽

Locally Advanced ◽

Phase 2 ◽

Single Center ◽

First Line ◽

Open Label ◽

First Line Therapy ◽

Line Therapy ◽

Phase 2 Study ◽

Penile Squamous Cell Carcinoma

Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(20)30275-1 ◽

2020 ◽

Vol 7 (11) ◽

pp. e808-e815 ◽

Cited By ~ 1

Author(s):

Bruce D Cheson ◽

Nancy L Bartlett ◽

Betsy LaPlant ◽

Hun J Lee ◽

Ranjana J Advani ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Brentuximab Vedotin ◽

Phase 2 ◽

First Line ◽

First Line Therapy ◽

Phase 2 Trial ◽

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

Annals of Oncology ◽

10.1093/annonc/mds213 ◽

2013 ◽

Vol 24 (1) ◽

pp. 75-83 ◽

Cited By ~ 338

Author(s):

M. Reck ◽

I. Bondarenko ◽

A. Luft ◽

P. Serwatowski ◽

F. Barlesi ◽

...

Keyword(s):

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Extensive Disease ◽

Double Blind ◽

First Line Therapy ◽

Phase 2 Trial ◽

Multicenter Phase ◽

2355 Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first- line therapy in patients with metastatic pancreatic adenocarcinoma. A GERCOR randomized phase II study (AFUGEM)

European Journal of Cancer ◽

10.1016/s0959-8049(16)31271-0 ◽

2015 ◽

Vol 51 ◽

pp. S453-S454

Author(s):

J.B. Bachet ◽

P. Hammel ◽

J. Desrame ◽

B. Chibaudel ◽

P. Debourdeau ◽

...

Keyword(s):

Metastatic Pancreatic Adenocarcinoma

Phase Ii ◽

Phase Ii Study ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Randomized Phase Ii ◽